HITLAB Releases Evidence Report on MedsEngine®, Validating Nation-Leading Chronic Disease Control Outcomes in Primary Care
Independent Evaluation Confirms: 92% Blood Pressure Control Sustained for 10 Consecutive Years Across 14,000+ Patients which is More Than Double the US National Average with Validated ROI of 20–30x.
NEW YORK, NY — May 2026 — HITLAB, the independent healthcare innovation and research laboratory affiliated with Columbia University, today released its Summary of Evidence Paper on MedsEngine®. HITLAB was engaged to conduct an independent, structured evaluation of the MedsEngine platform and its supporting clinical evidence base. The evaluation, completed in March 2026, encompassed a full walkthrough of all four disease modules, clinical workflow integration assessment, usability analysis using the Nielsen heuristic framework, comprehensive review of the peer-reviewed evidence, and economic value analysis.
The Clinical Problem MedsEngine Addresses: Transforming Chronic Disease Management
The United States spends $4.9 trillion annually on healthcare, with 84% consumed by chronic disease management. Despite decades of detailed clinical guidelines from the AHA, ACC, HFSA, and ADA, chronic diseases achieve treatment targets less than half of the time. National blood pressure control has remained below 50% for decades . Under the updated 2025 AHA/ACC threshold of <130/80 mmHg, the control rate falls further to 21%. HITLAB’s evaluation identifies a core barrier: physicians managing patients with hypertension, diabetes, heart failure, and high cholesterol must synthesize more than 855 pages of guidelines and evaluate approximately 160 patient-specific variables per encounter — all within a standard clinical visit. No practitioner can reliably execute this in real time. Existing EHR tools surface data but do not synthesize it into patient-specific action.
What HITLAB Evaluated: MedsEngine Real-time Point of Care Advisor for Clinicians
MedsEngine is a real-time, EHR-integrated clinical decision support platform built by physicians for primary care clinicians. Via a single-button launch from within the EHR, it automatically retrieves pertinent patient data through FHIR integration — labs, vitals, medications, comorbidities, and hemodynamic parameters — and returns a personalized, guideline-directed medication recommendation in under 10 seconds, across four disease modules: hypertension, high cholesterol, type 2 diabetes, and heart failure. No manual data entry is required. No separate login. No changes to the existing EHR build.
A central clinical differentiator is MedsEngine’s use of non-invasive impedance cardiography (ICG) to identify the hemodynamic root cause of each patient’s elevated blood pressure. HITLAB’s analysis of 22,346 ICG measurements confirms that 53% of hypertensive patients have a hemodynamic phenotype that standard first-line drug classes are unlikely to address adequately — a finding that helps explain why population-level BP control has remained below 50% for decades despite guideline availability. The platform uses deterministic, rules-based clinical logic — the same guidelines, executed the same way, for every patient, with full transparency and auditability.
- Hypertension: >92% blood pressure control to <140/90 sustained for 10 consecutive years at PriMED Physicians (Dayton, OH); >85% at Premier Medical Associates/Allegheny Health Network (Pittsburgh, PA) — against a US national average of 48%. Control achieved in fewer than 2 office visits on average across all racial groups, including populations that are 85% Non-White and 59% Medicare/Medicaid/uninsured.
- Cardiovascular Outcomes: MedsEngine users outperform MI and stroke rates when compared to SPRINT trial benchmarks in an older, higher-risk patient population. Cerebral and MI event rates are comparable to those of a population more than 15 years younger without hypertension.
- Diabetes: Calculates a personalized A1c goal synthesizing 35 patient-specific EHR factors.
- Cholesterol: Operationalizes the complete 120-page AHA/ACC guideline with all 77 patient-specific factors. Supports use of HCPCS G0446 billing generating approximately $25,000 net income per physician annually.
- Heart Failure: Enables primary care physicians to safely advance patients toward guideline-directed quadruple therapy. One MedsEngine user increased patients on triple therapy at maximum GDMT dose from 0% to 26% within one year of assuming care.
- Patient Activation & Medication Adherence: The platform generates a personalized patient summary report at the point of care, written at an appropriate reading level with Red/Yellow/Green visual risk displays. HITLAB confirms this directly supports patient activation and medication adherence — a major driver of sustained chronic disease control.
- Economic Value: Validated ROI of 20–30x for health system and payer partners. Control has demonstrated savings of $2,500/yr. for hypertension, $1,956/yr. for diabetes, and $780/yr. for cholesterol. Directly improves HEDIS measures, Star Ratings, CBP, GSD, MAC, MAD, and MAH.
“MedsEngine is among the most clinically rigorous and outcomes-validated decision support platforms HITLAB has evaluated. In a landscape crowded with digital health promises, MedsEngine delivers something rare: a decade of real-world evidence that durably moves the needle on chronic disease control at scale.”— Stan Kachnowski, PhD, MPA — Chair, HITLAB
Conclusion – MedsEngine Delivers a Differentiated, No Hallucination Solution for Primary Care
HITLAB’s overall assessment is that MedsEngine represents a mature, clinically credible, and strategically differentiated platform built on Deterministic Logic without risk of hallucinations within the current generation of AI clinical care solutions. It combines a decade of longitudinal real-world evidence with enterprise-grade technical infrastructure, a glass-box recommendation model that is fully explainable and auditable, and a clinical design refined through direct physician use. It has demonstrated the ability for primary care clinicians to reduce time looking at a computer screen and to engage in meaningful conversations with patients that support patient activation and medication adherence.
MedsEngine is a validated solution ready for scaled deployment across health systems, payers, employer owned medical clinics, medical group practices and primary care organizations. HITLAB recommends it as a priority platform for any organization accountable for chronic disease outcomes and value-based care performance.
MedsEngine is SOC 2 Type II certified and easily integrates with multiple EHR platforms, including Epic, using FHIR Smart-on-FHIR technology.
About HITLAB
About MedsEngine
MedsEngine is a real-time, EHR-integrated real-time, clinical decision support platform built by physicians for primary care clinicians. The platform today delivers personalized, guideline-directed medication recommendations at the point of care for hypertension, high cholesterol, type 2 diabetes, and heart failure. MedsEngine uses deterministic, rules-based clinical logic, executing AHA, ACC, HFSA, and ADA guidelines in real time with full transparency and auditability. MedsEngine has achieved and sustained >92% blood pressure control for 10 consecutive years across more than 14,000 patients
Share the article:
Learn More
